TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37710315

Group type: EXPERIMENTAL
Intervention: 2-arachidonoyl-lysophatidylcholine (2-AA-LPC) in carotid plaques from T2DM patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic inflammation markers (hsCRP, IL-1β)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxysterols, triglyceride levels, HDL levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of 2-AA-LPC with inflammatory markers within plaques
Number of subjects: 0
Study: 37710376

Group type: EXPERIMENTAL
Intervention: Suboptimal protein intake (0.2 g·kg-1·d-1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Moderate protein intake (1.2 g·kg-1·d-1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Excess protein intake (2.0 g·kg-1·d-1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Recommended protein intake for males (1.81 g·kg-1·d-1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Recommended protein intake for females (1.89 g·kg-1·d-1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Upper 95% confidence interval protein intake (~1.85 g·kg-1·d-1)
Number of subjects: 15
Study: 37711159

Group type: EXPERIMENTAL
Intervention: Quality of Life assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Needs assessment for caregivers
Number of subjects: 0
Study: 37711193

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg on day 1, ipilimumab 3 mg/kg plus nivolumab 1 mg/kg on day 22, and nivolumab 3 mg/kg on day 43 followed by chemoradiation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Multiparametric magnetic resonance imaging of the bladder
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA clearance
Number of subjects: 50
Study: 37711198

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (5ug), QID dosing
Number of subjects: 34
Study: 37711219

Group type: EXPERIMENTAL
Intervention: GBP510/AS03
Number of subjects: 4036

Group type: COMPARATOR
Intervention: ChAdOx1-S
Number of subjects: 4036
Study: 37711623

Group type: EXPERIMENTAL
Intervention: Vaccination with ITI-3000 (a cancer vaccine targeting MCPyV-LT)
Number of subjects: 0
Study: 37711718

Group type: EXPERIMENTAL
Intervention: 3 mg/kg of caffeine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 37711743

Group type: EXPERIMENTAL
Intervention: Joint intervention between general practitioners and community pharmacists, including training in motivational interviewing and 3 patient interviews after physician inclusion.
Number of subjects: 0
Study: 37711905

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 926

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 926
Study: 37712113

Group type: EXPERIMENTAL
Intervention: Daily stimulant use (methamphetamine, amphetamines or cocaine)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Daily stimulant use
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Weekly or more stimulant use
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 528
Study: 37712421

Group type: EXPERIMENTAL
Intervention: Maternal serum placental growth factor (PlGF) concentration and UmA Doppler category
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: EFW z score (Hadlock 3 formula/Marsal chart), gestational age, and UmA Doppler category
Number of subjects: 142
Study: 37712510

Group type: EXPERIMENTAL
Intervention: Stress hyperglycemia ratio (SHR)
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: High SHR (≥1.119) and NOAF
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: High SHR (≥1.119) and NOAF in diabetic patients
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: SHR
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: MACE
Number of subjects: 2145
Study: 37712585

Group type: EXPERIMENTAL
Intervention: Hepatitis B birth dose along with routine immunisation vaccines
Number of subjects: 296

Group type: COMPARATOR
Intervention: National vaccination schedule (control group)
Number of subjects: 296
Study: 37712725

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure of 85 - 90 mmHg in the initial 24 hours postoperatively
Number of subjects: 174

Group type: COMPARATOR
Intervention: Mean arterial pressure of 65 - 70 mmHg in the initial 24 hours postoperatively
Number of subjects: 174
Study: 37712728

Group type: EXPERIMENTAL
Intervention: Maximal expiratory pressure during induced cough (measured with slow instillation of 2mL of a 0.9% saline solution)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Maximal expiratory pressure (assessed with a unidirectional valve for 40 seconds with verbal encouragement)
Number of subjects: 80
Study: 37712729

Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional weaning
Number of subjects: 94
Study: 37712806

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation combined with chest physiotherapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional chest physiotherapy
Number of subjects: 122
Study: 37712908

Group type: EXPERIMENTAL
Intervention: Eculizumab treatment for >35 days
Number of subjects: 4118

Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 4118

Group type: COMPARATOR
Intervention: Untreated cohort
Number of subjects: 4118
Study: 37712964

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis) for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no probiotic supplementation)
Number of subjects: 30
Study: 37712984

Group type: EXPERIMENTAL
Intervention: Antiresorptive therapy (ART)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supportive periodontal care (SPC) without ART
Number of subjects: 100
Study: 37713020

Group type: EXPERIMENTAL
Intervention: Relugolix (120 mg orally once daily after single 360 mg loading dose)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Leuprolide (injections every 3 months)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Relugolix with losartan (n=103)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Relugolix with amlodipine (n=229)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Relugolix with metoprolol (n=88)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Relugolix with acetylsalicylic acid (n=259)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Relugolix with clopidogrel (n=43)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Relugolix with simvastatin (n=78)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Relugolix with concomitant CV agents
Number of subjects: 930
Study: 37713021

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 37713048

Group type: EXPERIMENTAL
Intervention: Hyper-inflammatory profiles
Number of subjects: 193

Group type: COMPARATOR
Intervention: Hypo-inflammatory profiles
Number of subjects: 193
Study: 37713090

Group type: EXPERIMENTAL
Intervention: Teclistamab (1.5 mg/kg SC weekly, preceded by step-up doses of 0.06 and 0.3 mg/kg)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Teclistamab
Number of subjects: 338
Study: 37713103

Group type: EXPERIMENTAL
Intervention: Live multistrain probiotics
Number of subjects: 68
Study: 37713133

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg
Number of subjects: 335
Study: 37713194

Group type: EXPERIMENTAL
Intervention: Household exposure to children under 6 years
Number of subjects: 682952

Group type: EXPERIMENTAL
Intervention: Household exposure to children in daycare facilities
Number of subjects: 682952

Group type: EXPERIMENTAL
Intervention: Household exposure to preschool children
Number of subjects: 682952

Group type: EXPERIMENTAL
Intervention: Household exposure to primary school children (aged 6-14 years)
Number of subjects: 682952

Group type: EXPERIMENTAL
Intervention: Household exposure to middle school children (aged 6-14 years)
Number of subjects: 682952

Group type: EXPERIMENTAL
Intervention: Household exposure to older children (aged 15-17 years)
Number of subjects: 682952
Study: 37713244

Group type: EXPERIMENTAL
Intervention: PrEPTECH telehealth intervention (web-based program)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (dynamic web page with publicly available informational resources about PrEP)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: PrEPTECH intervention
Number of subjects: 229
Study: 37713289

Group type: EXPERIMENTAL
Intervention: Multicomponent educational intervention including clinic-wide PrEP trainings, electronic health record prompt for PrEP counseling, educational videos in the waiting room.
Number of subjects: 1720
Study: 37713322

Group type: EXPERIMENTAL
Intervention: Intrauterine vacuum-induced hemorrhage control device
Number of subjects: 800
Study: 37713401

Group type: EXPERIMENTAL
Intervention: Replication-competent oncolytic adenovirus (Ad5-yCD/mutTKSR39rep-hIL-12)
Number of subjects: 15
Study: 37713527

Group type: EXPERIMENTAL
Intervention: 1 g intravenous cefoxitin
Number of subjects: 378

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 378
Study: 37713598

Group type: EXPERIMENTAL
Intervention: Subtenon Wharton's jelly-derived mesenchymal stem cells (WJ-MSC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Magnovision
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of WJ-MSC and Magnovision
Number of subjects: 80

Group type: COMPARATOR
Intervention: Natural course (control group)
Number of subjects: 80
Study: 37713657

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 1581

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1581
Study: 37713684

Group type: EXPERIMENTAL
Intervention: Ticagrelor and clopidogrel on top of aspirin (ADAPT)
Number of subjects: 18624

Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 18624

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study: 37714048

Group type: EXPERIMENTAL
Intervention: Baby-led weaning (BLW)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional complementary feeding (TCF)
Number of subjects: 52
Study: 37714168

Group type: EXPERIMENTAL
Intervention: Olaparib plus abiraterone
Number of subjects: 796

Group type: COMPARATOR
Intervention: Placebo plus abiraterone
Number of subjects: 796
Study: 37714386

Group type: EXPERIMENTAL
Intervention: Chinese version of the Columbia-Suicide Severity Rating Scale (C-SSRS)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 456
Study: 37714670

Group type: EXPERIMENTAL
Intervention: Ultra-Thin Descemet Stripping Automated Endothelial Keratoplasty (UT-DSAEK)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Descemet Membrane Endothelial Keratoplasty (DMEK)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: UT-DSAEK
Number of subjects: 220

Group type: COMPARATOR
Intervention: DMEK
Number of subjects: 220
Study: 37714726

Group type: EXPERIMENTAL
Intervention: Shockwave intravascular lithotripsy (IVL)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Rotational atherectomy (RA)
Number of subjects: 170
Study: 37714979

Group type: EXPERIMENTAL
Intervention: Melanin-targeted PET imaging
Number of subjects: 3
Study: 37715029

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy with thyroid dysfunction
Number of subjects: 73

Group type: COMPARATOR
Intervention: No thyroid dysfunction
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 73

Group type: COMPARATOR
Intervention: Female patients
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Anti-PD-1-induced thyroid dysfunction
Number of subjects: 73
Study: 37715123

Group type: EXPERIMENTAL
Intervention: SOFIA coordinated care program (extended structured consultations, group-based training of GPs and staff, handbook for signposting)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 87
Study: 37715147

Group type: EXPERIMENTAL
Intervention: Video intervention providing information on domestic violence and safety improving actions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group watching a video on maintaining a healthy pregnancy.
Number of subjects: 0
Study: 37715152

Group type: EXPERIMENTAL
Intervention: Microcurrent device applied for 60 min, 3 times per week for 4 weeks.
Number of subjects: 23
Study: 37715156

Group type: EXPERIMENTAL
Intervention: GILL eHealth intervention
Number of subjects: 258

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 258
Study: 37715173

Group type: EXPERIMENTAL
Intervention: PENG block
Number of subjects: 84

Group type: COMPARATOR
Intervention: Intravenous opioid
Number of subjects: 84
Study: 37715201

Group type: EXPERIMENTAL
Intervention: DIMS spectacle lenses
Number of subjects: 158

Group type: COMPARATOR
Intervention: SV spectacle lenses
Number of subjects: 158
Study: 37715203

Group type: EXPERIMENTAL
Intervention: mHealth intervention 'mindfulHeart'
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study: 37715222

Group type: EXPERIMENTAL
Intervention: Nitrate-containing beetroot juice
Number of subjects: 98

Group type: COMPARATOR
Intervention: Nitrate-deplete beetroot juice (placebo)
Number of subjects: 98
Study: 37715249

Group type: EXPERIMENTAL
Intervention: BCN-led group cognitive behavioural therapy (CBT)
Number of subjects: 23
Study: 37715270

Group type: EXPERIMENTAL
Intervention: Quizartinib combined with high-dose Ara-C plus mitoxantrone (HAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive salvage therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 37715283

Group type: EXPERIMENTAL
Intervention: Abdominal bracing during lifting tasks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Natural loaded breathing (without abdominal bracing)
Number of subjects: 31
Study: 37715294

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 404

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 404
Study: 37715369

Group type: EXPERIMENTAL
Intervention: ICD-10 code F11.10 (opioid abuse, uncomplicated)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: ICD-10 code F11.21 (opioid dependence, in remission)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: ICD-10 code F11.99 (opioid use, unspecified with unspecified opioid-induced disorder)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: ICD-10 codes F11.20, F11.23, and F11.90
Number of subjects: 307

Group type: COMPARATOR
Intervention: General findings regarding ICD code application
Number of subjects: 307
Study: 37715710

Group type: EXPERIMENTAL
Intervention: Optimizing sleep quality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improving mood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reducing hot flash quantity/interference
Number of subjects: 0
Study: 37715730

Group type: EXPERIMENTAL
Intervention: Indoximod-based combination therapy with oral temozolomide (200 mg/m2/day x 5 days in 28-day cycles)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Indoximod-based combination therapy with palliative conformal radiation
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Indoximod-based combination therapy
Number of subjects: 81
Study: 37715742

Group type: EXPERIMENTAL
Intervention: HOT-CRT (His-Purkinje conduction system pacing)
Number of subjects: 100

Group type: COMPARATOR
Intervention: BVP (Biventricular pacing)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HOT-CRT
Number of subjects: 100

Group type: COMPARATOR
Intervention: BVP
Number of subjects: 100
Study: 37715767

Group type: EXPERIMENTAL
Intervention: Youth Development Accounts (YDA) treatment, n=471 girls
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Integrated intervention combining YDA with multiple family group component, n=381 girls
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Control group, n=408 girls
Number of subjects: 1260
Study: 37715769

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 3656

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3656
Study: 37715773

Group type: EXPERIMENTAL
Intervention: High-risk plaque (HRP) on CTA
Number of subjects: 448

Group type: COMPARATOR
Intervention: No high-risk plaque (HRP) on CTA
Number of subjects: 448
Study: 37715820

Group type: EXPERIMENTAL
Intervention: Glycaemic intervention (high burden)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure intervention (medium burden)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triglyceride-lowering intervention (low burden)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia requiring medical assistance
Number of subjects: 0
Study: 37715858

Group type: EXPERIMENTAL
Intervention: Video Plethysmography (VPPG)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard medical device (Welch Allyn)
Number of subjects: 216
Study: 37715860

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan treated monthly (PM)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan treated every other month (PEOM)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sham-treated
Number of subjects: 144

Group type: COMPARATOR
Intervention: Untreated fellow eyes
Number of subjects: 144
Study: 37715890

Group type: EXPERIMENTAL
Intervention: Screening algorithm for PAD
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Optimized screening algorithm
Number of subjects: 104
Study: 37715936

Group type: EXPERIMENTAL
Intervention: Lower caregiver preparedness
Number of subjects: 424
Study: 37715999

Group type: EXPERIMENTAL
Intervention: NexoBrid
Number of subjects: 75

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 75
Study: 37716204

Group type: EXPERIMENTAL
Intervention: ACT-IN plus treatment as usual (TAU)
Number of subjects: 46

Group type: COMPARATOR
Intervention: TAM plus treatment as usual (TAU)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Both ACT-IN and TAM
Number of subjects: 46
Study: 37716360

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4047

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4047

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (women)
Number of subjects: 4047

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (men)
Number of subjects: 4047
Study: 37716365

Group type: EXPERIMENTAL
Intervention: Bivalent SARS-CoV-2 recombinant protein vaccine (5 μg of ancestral [D614] and 5 μg of beta [B.1.351] variant spike protein, with AS03 adjuvant), administered as two 0.5 mL intramuscular injections, 21 days apart.
Number of subjects: 13002

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline), administered as two 0.5 mL intramuscular injections, 21 days apart.
Number of subjects: 13002
Study: 37716443

Group type: EXPERIMENTAL
Intervention: Iron-folic acid (IFA) supplementation
Number of subjects: 3123

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplements (MMS)
Number of subjects: 3123

Group type: COMPARATOR
Intervention: Standard nutrition education (Control)
Number of subjects: 3123
Study: 37716448

Group type: EXPERIMENTAL
Intervention: DAPT plus rivaroxaban 2.5mg twice daily for 4 weeks
Number of subjects: 560

Group type: COMPARATOR
Intervention: DAPT alone
Number of subjects: 560
Study: 37716474

Group type: EXPERIMENTAL
Intervention: Double-tracer gas single-breath washout (DTG-SBW) measurement
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Age, body composition, and wheeze
Number of subjects: 1782
Study: 37716519

Group type: EXPERIMENTAL
Intervention: Combined endurance and resistance eccentric training (ECC) for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional training (CON) for 4 weeks
Number of subjects: 30
Study: 37716893

Group type: EXPERIMENTAL
Intervention: Brief Cognitive-Behavioural Therapy (CBT) intervention, six sessions
Number of subjects: 21

Group type: COMPARATOR
Intervention: Treatment-as-usual (control condition)
Number of subjects: 21
Study: 37716952

Group type: COMPARATOR
Intervention: atrasentan 0.75 mg/day
Number of subjects: 2037

Group type: COMPARATOR
Intervention: atrasentan 1.25 mg/day
Number of subjects: 2037

Group type: EXPERIMENTAL
Intervention: HOMA-IR increase
Number of subjects: 2037
Study: 37716967

Group type: EXPERIMENTAL
Intervention: Resilientchild.dk web-based intervention
Number of subjects: 0
Study: 37716990

Group type: EXPERIMENTAL
Intervention: Routine use of rapid diagnostic testing at admission
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Pharmacist-led de-escalation after 48 hours for clinically stable patients with negative cultures
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Combination of rapid diagnostic testing and pharmacist-led de-escalation
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Detection of respiratory viruses
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Treatment with anti-viral medications
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Positive pneumococcal urinary antigen test
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: De-escalation by 72 hours from admission
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Re-escalation to ESA after de-escalation
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Total duration of any antibiotic
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: 14-day in-hospital mortality
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Intensive care unit transfer after admission
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Healthcare-associated C. difficile infection
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Acute kidney injury
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Total inpatient cost
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Hospital length-of-stay
Number of subjects: 12000
Study: 37717001

Group type: EXPERIMENTAL
Intervention: 3D reconstruction (volume rendering) of the chest CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2D reconstruction (axial, coronary, and sagittal) of the chest CT
Number of subjects: 0
Study: 37717072

Group type: EXPERIMENTAL
Intervention: Mild sleep restriction (1.5 hours less than habitual sleep) for 6 weeks
Number of subjects: 35
Study: 37717543

Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) for neuroticism
Number of subjects: 406

Group type: COMPARATOR
Intervention: Control processing in difficult situations
Number of subjects: 406
Study: 37717589

Group type: EXPERIMENTAL
Intervention: Appendicectomy scheduled within 8 hours
Number of subjects: 1822

Group type: COMPARATOR
Intervention: Appendicectomy scheduled within 24 hours
Number of subjects: 1822